Qube Research & Technologies (QRT)
MRNA icon

Qube Research & Technologies (QRT)’s Moderna MRNA Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Sell
195,100
-829,800
-81% -$42.9M 0.01% 1102
2026
Q1 		$52.1M Sell
1,024,900
-785,800
-43% -$36.7M 0.06% 416
2025
Q4 		$53.4M Buy
1,810,700
+230,400
+15% +$6.26M 0.05% 457
2025
Q3 		$40.8M Sell
1,580,300
-270,000
-15% -$7.53M 0.04% 552
2025
Q2 		$51M Buy
1,850,300
+598,000
+48% +$15.7M 0.05% 457
2025
Q1 		$35.5M Buy
1,252,300
+740,300
+145% +$26.3M 0.04% 518
2024
Q4 		$21.3M Sell
512,000
-27,000
-5% -$1.29M 0.03% 696
2024
Q3 		$36M Buy
539,000
+428,400
+387% +$39.3M 0.05% 442
2024
Q2 		$13.1M Sell
110,600
-133,600
-55% -$16.9M 0.02% 800
2024
Q1 		$26M Sell
244,200
-164,000
-40% -$16.5M 0.04% 483
2023
Q4 		$40.6M Buy
408,200
+337,000
+473% +$28.3M 0.08% 309
2023
Q3 		$7.35M Buy
+71,200
New +$7.94M 0.02% 763

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MRNA Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its Moderna (MRNA) stake by 29% in Q2 2026, buying an estimated $10.7M and bringing the position to 907,157 shares worth $63.5M. The position accounts for 0.06% of the portfolio, ranked #416.

Qube Research & Technologies (QRT) first reported a position in MRNA in Q1 2020 and has held it in 14 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Qube Research & Technologies (QRT) held 907,157 shares of Moderna worth $63.5M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 206,465 Moderna shares in Q2 2026, an estimated $10.7M.
  • Moderna made up 0.06% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #416 holding.
  • Qube Research & Technologies (QRT) first reported a position in Moderna in Q1 2020 and has held it in 14 quarters since.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.